Piscataway, NJ, August 28, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Capecitabine Tablets, USP to its product line.
Capecitabine Tablets, USP is a nucleoside metabolic inhibitor indicated for:
Colorectal Cancer
• adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen.
• perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy.
• treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.
Breast Cancer
• treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated.
• treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.
Gastric, Esophageal, or Gastroesophageal Junction Cancer
• treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen.
• treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.
Pancreatic Cancer
• the adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen
Capecitabine Tablets, USP are available in 60 count bottle of 150 and 500 mg as well as 500mg in 120 count.
To learn more about Capecitabine Tablets, USP please visit https://www.camberpharma.com/capecitabine
